![]() |
Technical Data |
|
V2110-07D |
Vascular Endothelial Growth Factor, Recombinant, Mouse (VEGF) |
2ug 10ug 100ug |
| Growth Factors, Cytokines | Storage: -70°CShipping: Blue Ice |
|
Vascular endothelial growth factor-A was originally isolated from tumor cells and referred to as Tumor Angiogenesis Factor or Vascular Permeability Factor. Although expressed at high levels in certain tumor-derived cells it is produced by a wide variety of cell types. In addition to stimulating vascular growth and vascular permeability it may play a role in stimulating Vasolidation via nitric oxide-dependent pathways. Alternative splicing of the mRNA for VEGF-A results in several isoforms of the protein being produced. Rat and bovine VEGF are one amino acid shorter than the human factor, and the bovine and human sequences show a homology of 95 percent. In contrast to other factors mitogenic for endothelial cells such as FGF-1, FGF-2 and PDGF, VEGF is synthesized as a precursor containing a typical hydrophobic secretory signal sequence of 26 amino acids. Glycosylation is not required for efficient secretion of VEGF. Biological Activity: The biological activity is determined by the dose-dependent stimulation of the proliferation of human umbilical vein endothelial cells (HUVEC) using a concentration range of 1.0-5.0ng/ml. AA Sequence: MAPTTEGEQK SHEVIKFMDV YQRSYCRPIE TLVDIFQEYP DEIEYIFKPS CVPLMRCAGC CNDEALECVP TSESNITMQI MRIKPHQSQH IGEMSFLQHS RCECRPKKDR TKPEKHCEPC SERRKHLFVQ DPQTCKCSCK NTDSRCKARQ LELNERTCRC DKPRR Storage and Stability: Lyophilized powder may be stored at -20°C. Stable for 12 months at -20°C. Reconstitute with sterile ddH2O, aliquot and store at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer. Molecular Weight: 39.1kD |
Source: Recombinant, murine, E. coli Purity: 95% as determined by RP-HPLC; Reducing and non-reducing SDS-PAGE. Form: Supplied as a lyophilized powder. Reconstitute with sterile dH2O PBS to 0.1-1mg/ml, which can be further diluted into other aqueous solutions. Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological. |
|
|
1. Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer Cell 2007 Jan;11(1):53-67 2. [The relationship between plasma level of VEGF or soluble Flt-1 and efficacy of hepatic arterial chemotherapy in patients with liver metastasis of colorectal cancer] Gan To Kagaku Ryoho 2006 Nov;33(12):1841-4 3. VEGF, FGF1, FGF2 and EGF gene polymorphisms and psoriatic arthritis. BMC Musculoskelet Disord 2007 Jan 4;8:1 4. Impact of VEGF expression on the physiological characteristics of clonal cell lines. In Vivo 2006 N ov-Dec;20(6B):815-21 5. Expression of VEGF and its receptors and angiogenesis in bone and soft tissue tumors. Anticancer Res 2006 Nov-Dec;26(6B):4307-11 6. Stimulation of apical and basolateral VEGF-A and VEGF-C secretion by oxidative stress in polarized retinal pigment epithelial cells. Mol Vis 2006 Dec 22;12:1649-59
|
||